TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* One of the following histologically confirmed diseases for which no curative surgical, radiotherapy, or chemotherapy programs are available and standard therapy offers, at best, a modest clinical benefit~  * Solid tumors~ * Gliomas~ * Non-Hodgkin's lymphoma~* Primary and metastatic CNS malignancies are eligible~* Evaluable or measurable disease~* CD34 count at least 2.0 cells/μL~* No bone marrow involvement~  * Histologically negative bone marrow biopsy~PATIENT CHARACTERISTICS:~Age:~* 18 to 70~Performance status:~* ECOG 0-2~Life expectancy:~* At least 12 weeks~Hematopoietic:~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin at least 8.5 g/dL~Hepatic:~* Bilirubin no greater than 1.5 mg/dL~* AST and ALT less than 2.5 times normal~* Prothrombin time less than 1.2 times normal~Renal:~* Creatinine no greater than 2.0 mg/dL~Cardiovascular:~* No acute cardiac disease by EKG~Pulmonary:~* No symptomatic pulmonary disease~Other:~* HIV negative~* No other severe comorbid conditions~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 2 months after study completion~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* See Chemotherapy~* No prior hematopoietic stem cell transplantation~Chemotherapy:~* No prior high-dose chemotherapy~* Prior adjuvant chemotherapy allowed~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior radiotherapy to 25% or more of bone marrow~Surgery:~* Not specified~Other:~* At least 4 weeks since prior myelosuppressive therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Distraction Protocol for Peripheral Intravenous (IV) Placement in the Pediatric Emergency Department

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 4 - 9~* Requiring IV placement for medical care in emergency department~* Child cognitively normal~Exclusion Criteria:~* No significant chronic medical conditions~* No IV in past 3 years

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 9 Years
- Healthy Volunteers: f

Study Arms:
- Distraction (Type: EXPERIMENTAL): Parent given brief teaching session on concept of distraction, and parent and child given 3 distraction toys/tools to assist with peripheral intravenous line placement.
- Routine care (Type: OTHER): Patient managed as routine care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than 18 years~* Positive SARS-CoV-2 testing or consistent clinical syndrome (based on clinical picture e.g. characteristic infiltrates on chest x-ray, laboratory findings, and with agreement by two physicians) in patients under investigation (PUIs).~* Onset of symptoms \< 7 days from date of enrollment~* Oxygen saturation of \>94% on room air with defined risk factors (Table 1) consistent with moderate disease OR oxygen saturation of \< 94% on room air consistent with severe disease~* Ability and willingness to comply with study procedures~Exclusion Criteria:~* QTc greater than 450 milliseconds on screening EKG~* Pregnant or lactating women~* Inability to take oral pills or inability to use a feeding tube~* Inability to obtain informed consent either from the patient or from the next of kin if patient is incapacitated. For the purpose of this study obtaining a verbal consent from a family member on the phone with a witness will be considered acceptable since there is a 'no visitor' policy in force at hospitals.~* Patients requiring ICU level care~* use of azithromycin or hydroxychloroquine within 30 days prior to admission

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: NO_INTERVENTION): Supportive Care only
- Arm B (Type: EXPERIMENTAL): Hydroxychloroquine 400 mg po bid on Day 1 Hydroxychloroquine 200 mg po bid Days 2 through 5
- Arm C (Type: EXPERIMENTAL): Hydroxychloroquine as in Arm B AND Azithromycin 500 mg po on Day 1 Azithromycin 250 mg po days 2 through 5

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years.~* Patients with new onset of disease evidenced by diarrhea (≥ 3 unformed stools within 24 hours), and one or more of the following symptoms of CDAD:~  * abdominal pain or cramps~ * peripheral leukocytosis~ * fever~* C. difficile toxin A or B detected in a stool specimen obtained within 3 days before enrollment by enzyme immunoassay.~* Patients willing to avoid the following medications during the study:~  * oral and intravenous metronidazole~ * oral vancomycin~ * anti-peristaltic drugs~ * opiates (patients on opiates may be included in the study if they were taking opiates prior to enrollment and the dose is not increased during the study)~ * Saccharomyces cerevisiae (baker's yeast)~ * Lactobacillus GG~ * cholestyramine~ * colestipol~Exclusion Criteria:~* Patients with other known causes of diarrhea or colitis (e.g., Shigella, Salmonella, Cryptosporidium parvum, Giardia lamblia, Entamoeba histolytica, inflammatory bowel disease, irritable bowel syndrome, advanced AIDS or chemotherapy for malignancy).~* Patients that commonly have 3 or more stools per day and/or severe abdominal pain in the absence of CDAD.~* Patients with severe lactose intolerance.~* Patients with more than 1 recurrence of CDAD during the 6 months prior to enrollment.~* Patients unable to take oral medications.~* Use within 1 week of enrollment of any drug or therapy with anti-C. difficile activity such as oral or intravenous metronidazole and oral vancomycin. \[Patients that have taken up to 3 doses of metronidazole or vancomycin can be included in the study\].~* Females of child bearing age who are either pregnant, breast-feeding or not using birth control and are sexually active.~* Patients who are either clinically unstable (e.g., fulminant disease patients with signs of toxic megacolon, imminent perforation, colectomy or death) or unlikely to live throughout the 31-day duration of the study due to underlying illness.~* History of hypersensitivity to nitazoxanide or vancomycin or any active ingredient in the formulations.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Parafricta Bootees vs UK Standard Care to Prevent Heel Pressure Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~The eligibility criteria for this study at the time of recruitment were:~* Adult of age 18 years or over~* Admitted to secondary care in an in-patient hospital (with no specified interval from admission to hospital to study recruitment)~* Bedbound or unable to walk independently and requiring assistance to transfer to a chair~* 'Very high' risk group for pressure ulceration (defined by a Waterlow Score of 20 or more)~* No existing heel pressure ulcers of EPUAP/NPUAP/PPPIA Category 1 or above or any other type of wound on the feet.~* Patient was not being treated with pressure offloading boots.~* Patient was not being treated with a heel cast.~Exclusion Criteria:~• Patients with a single or double lower limb amputation were not eligible to participate in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard care alone (Type: NO_INTERVENTION): Patients randomly allocated to standard care will be cared for on the appropriate mattress indicated for use in that participating centre according to local policy e.g. foam mattress or dynamic air mattress. Standard care may also include a mattress overlay or the use of a wedge or pillows to maintain the position of the participant, or pressure offloading boots on the foot if the need arises during the study period.
- Parafricta bootees plus standard care (Type: EXPERIMENTAL): Patients randomly allocated to Parafricta plus standard care will be cared for on the appropriate mattress as above and care may possibly include a mattress overlay or the use of a wedge or pillows. Participants will in addition be issued with Parafricta bootees (one pair and up to two spare pairs). The patient and clinical staff and the patient's carers will be instructed in the use of Parafricta bootees, which are intended to be worn throughout the day and night and removed only for normal daily washing or examination of the patient's feet. Either the slip-on bootees or the Velco-closure bootees will be selected for the participant at the judgment of the clinical ward nurses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: VIrtual REality Glasses for the Enhancement of Acute BRACHYtherapy Tolerance for Endometrial Cancer Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients over 18 years old.~* Patients with endometrial cancer, with histological type I and II, regardless of the degree of differentiation.~* Patients with stage I, II or III endometrial cancer according to the FIGO classification.~* Patients treated with high-dose-rate vaginal cuff brachytherapy, with curative intent.~* Patients affiliated or entitled to a social security scheme.~* Patients who received information about the study and co-signed with the investigator the consent to participate at the study.~Exclusion Criteria:~* Patients with stage IV endometrial cancer according to FIGO classification.~* Patients presenting recurrence of endometrial cancer.~* Pregnant or nursing women.~* Patients under protection of justice or unable to give consent.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Virtual Reality Helmet (Type: EXPERIMENTAL): Patients will use a virtual reality helmet during brachytherapy applicator's setting up. The use of virtual reality helmet has already been assessed during oncologic treatments, and seems to reduce pain and anxiety. The use of virtual reality helmet has never been assessed to reduce the pain or anxiety associated with brachytherapy applicators' setting up.
- No Virtual Reality Helmet (Type: ACTIVE_COMPARATOR): Patient wont use virtual reality helmet during brachytherapy applicator setting up, as in current practice.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Systemic Anti-Cancer Therapies in the Cerebrospinal Fluid (CSF) of Patients With Advanced Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Metastatic cancer patients on systemic anti-cancer therapy (chemotherapy, endocrine therapy, HER2 targeted therapy, immune therapy).~2. Patients must be able to have a lumbar puncture within 2 half-lives of the last dose of systemic therapy.~3. Patients undergoing an LP for any reason with known advanced cancer on systemic anti-cancer therapy are eligible.~4. Patients with new or previously treated brain metastases are eligible.~5. Patients may have received prior stereotactic radiosurgery to the brain and/or whole brain radiation.~6. No limitations on prior systemic or intrathecal therapies.~7. There are no restrictions on systemic therapy at enrollment.~8. Laboratory criteria: normal renal function: creatinine \< 1.5 x upper limit of normal (ULN)), liver function: bilirubin \< 1.5 x ULN, transaminases \< 2 x ULN, except in known hepatic disease, wherein may be \< 5 x ULN, and blood counts: WBC ≥ 2.0, Neutrophils ≥1500, platelets ≥100,000, Hemoglobin ≥ 10.~9. Age \> 18 years~10. Patients must have the ability to give informed consent.~11. Patients must have a signed informed consent form prior to enrollment on study.~Exclusion Criteria:~1. No history of lumbar surgery or other pre-existing spinal conditions that would preclude a safe, reliable lumbar puncture.~2. Patients should have no significant psychiatric illness or medical illness that would preclude the ability to comply with the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: MOD Diet in Gestational Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women between the ages 18-40 years old~* A positive GDM diagnosis at 24-28 weeks gestation~* GDM management by diet alone~* willing to consume food provided in the study~* English speaking~Exclusion Criteria:~* multiple gestation~* hypertriglyceridemia (fasting TG \>400 mg/dL)~* suspected overt diabetes (previous A1c≥6.5)~* smoker~* fasting glucose \>110mg/dL~* overt cognitive impairment~* presence of risk factors for placental insufficiency or growth restriction (e.g.~hypertension, renal disease, history of preeclampsia, use of β-blockers)~* history of preterm birth~* other major medical disorder

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Standard Care Diet (Type: ACTIVE_COMPARATOR): After the controlled feeding study, participants in this group will follow the standard care diet for the remainder of pregnancy with the assistance of a study dietitian. The standard care study diet will provide the standard 40% Carb/20% Pro/40% Fat as energy, distributed consistently across 3 meals and 2 snacks.
- Macro-Optimized Diet (MOD) (Type: EXPERIMENTAL): After the controlled feeding study, participants in this group will follow the MOD diet for the remainder of pregnancy with the assistance of a study dietitian. The MOD diet will differ from control by macronutrient distribution at breakfast specifically, but also at each eating occasion, although the daily macronutrient distribution is equal to the control diet. At breakfast, the MOD diet will provide 10% Carb/30% Pro/60% Fat.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Diflunisal in HIV-infected Adults

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult men and women aged 19 years or over~2. HIV positive by ELISA and Western blot, at least 3 months prior to screening~3. No antiretroviral therapy within 3 months prior to screening~4. Plasma HIV RNA (viral load) \> 2,500 copies/mL at screening~5. Current CD4 cell count \>350 cells/mm3 at screening~6. Adequate renal function as demonstrated by eGFR \>60 mL/min. at screening~Exclusion Criteria:~1. Pregnancy or breast-feeding~2. Any HIV-associated symptom or condition (e.g. nephropathy) for which standard antiretroviral therapy is indicated immediately~3. History of peptic ulcer and/or gastrointestinal bleeding~4. Allergy to ASA, other salicylates, or NSAIDs~5. Currently receiving treatment with an ACE inhibitor, ASA, anticoagulants, antacids containing aluminum hydroxide, cyclosporine, diuretics, systemic glucocorticoids, lithium, methotrexate, or other NSAIDs~6. Significant hepatic impairment or active liver disease - screening AST, ALT, or bilirubin \>2.5x upper limit of normal (ULN)~7. Hyperkalemia - screening serum potassium \>5.5 mmol/L~8. Anemia - screening hemoglobin \<85 g/L

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diflunisal (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients aged \>/=18 years~* Adequate bone marrow, liver, and renal functions~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2~* Diseases as defined below:~PART1~* Subjects with CLL with either del(17p) by FISH or TP53 mutation who have received ≥1 prior therap(ies) and the last prior regimen must have included venetoclax plus an anti-CD20 antibody and/or a BTKi and did not produce complete remission. Subjects with CLL with either del(17p) by FISH or TP53 mutation who have received ≥2 prior regimens and are intolerant to BTKi and/or venetoclax are also eligible.~or~* Subjects with CLL transformed to DLBCL who have relapsed after, or been refractory, to at least 1 prior line of therapy for DLBCL~PART2~* Subjects with CLL who are currently on an approved BTKi (monotherapy only) at the dose and schedule per the local label for ≥ 12 months who have only achieved SD, PR or PRL~Exclusion Criteria:~* Active clinically serious infections of Grade \> 2; requiring parenteral therapy~* Subjects who have new or progressive brain or meningeal or spinal metastases.~* Anticancer chemotherapy or immunotherapy during the study or within one week prior to the first dose of study drug~* Major surgery or significant trauma within 4 weeks before the first dose of study drug~* Allogeneic bone marrow transplant or stem cell rescue within 4 months before first dose of study drug; patients must have completed immunosuppressive therapy before enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Monotherapy of VIP152 (Type: EXPERIMENTAL): Investigating VIP152 in a monotherapy cohort in patients with high-risk CLL and Richter Syndrome
- VIP152 in combination with BTKi (Type: EXPERIMENTAL): Investigating VIP152 in combination with a BTKi in patients with CLL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must have confirmed NSCLC (squamous, adeno- and large cell anaplastic carcinoma)stage III B or Stage IV.~No prior chemotherapy regimen Patients must have adequate organ and marrow function~Exclusion Criteria:~* Untreated symptomatic brain metastasis Patients with known HIV positivity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy